Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison
Aim To compare the efficacy of tirzepatide 10 and 15 mg with semaglutide 2.4 mg using an indirect treatment comparison. Materials and Methods Using SURMOUNT‐1 and STEP 1 trial data, mean percentage change in body weight from baseline and odds ratio (OR) of achieving 5% or greater weight loss were co...
Gespeichert in:
| Veröffentlicht in: | Diabetes, obesity & metabolism obesity & metabolism, 2023-09, Vol.25 (9), p.2626-2633 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2633 |
|---|---|
| container_issue | 9 |
| container_start_page | 2626 |
| container_title | Diabetes, obesity & metabolism |
| container_volume | 25 |
| creator | Roux, Carel W. Hankosky, Emily R. Wang, Duzhe Malik, Raleigh Yu, Maria Hickey, Ana Kan, Hong Bunck, Mathijs C. Stefanski, Adam Garcia‐Perez, Luis‐Emilio Wharton, Sean |
| description | Aim
To compare the efficacy of tirzepatide 10 and 15 mg with semaglutide 2.4 mg using an indirect treatment comparison.
Materials and Methods
Using SURMOUNT‐1 and STEP 1 trial data, mean percentage change in body weight from baseline and odds ratio (OR) of achieving 5% or greater weight loss were compared between tirzepatide 10 and 15 mg at week 72 and semaglutide 2.4 mg at week 68 using matching‐adjusted indirect comparison of the efficacy estimand. Sensitivity analyses were completed using different methods, including the Bucher method, also using different estimands and/or time points.
Results
Greater reductions in percentage change in body weight were observed with tirzepatide 10 and 15 mg versus semaglutide 2.4 mg (tirzepatide 10 mg mean difference: −4.67% [95% CI −5.91%, −3.43%]; tirzepatide 15 mg mean difference: −5.92% [95% CI −7.16%, −4.68%]; both P |
| doi_str_mv | 10.1111/dom.15148 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2828752534</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2828752534</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3608-a0f8b5c41b8951155bcd1d6c2891f745eb0bedf897ff6030485513d06ec8b9bb3</originalsourceid><addsrcrecordid>eNp10D9P3DAYx3GrKioH7dA3UHlshxx2bCdOtxMFWukQC8yR_zw-XCXx1fYJHWJg5W3ySggXQF3w4mf46Dv8EPpKyZyO78iGfk4F5fIDmlFesYKysvq4u8tCNqTcRwcp_SWEcCbrT2if1YyPJ5-hu0sfb2GtsreAKcFqsJiKx_uHfoVN6NcqgsU3Pl_jBL1adZsdLOd8Ii5EnK8B5wgq9zBkHBwOGpLP2594MWA_WB_B5P_ElPUpDJ_RnlNdgi8v_yG6Oj25PP5dLC_O_hwvloVhFZGFIk5qYTjVshGUCqGNpbYypWyoq7kATTRYJ5vauYowwqUQlFlSgZG60Zodou9Tdx3Dvw2k3PY-Geg6NUDYpLaUpaxFKRgf6Y-JmhhSiuDadfS9ituWkvZ57HYcu92NPdpvL9mN7sG-ydd1R3A0gRvfwfb9Uvvr4nxKPgFXdor3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2828752534</pqid></control><display><type>article</type><title>Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Roux, Carel W. ; Hankosky, Emily R. ; Wang, Duzhe ; Malik, Raleigh ; Yu, Maria ; Hickey, Ana ; Kan, Hong ; Bunck, Mathijs C. ; Stefanski, Adam ; Garcia‐Perez, Luis‐Emilio ; Wharton, Sean</creator><creatorcontrib>Roux, Carel W. ; Hankosky, Emily R. ; Wang, Duzhe ; Malik, Raleigh ; Yu, Maria ; Hickey, Ana ; Kan, Hong ; Bunck, Mathijs C. ; Stefanski, Adam ; Garcia‐Perez, Luis‐Emilio ; Wharton, Sean</creatorcontrib><description>Aim
To compare the efficacy of tirzepatide 10 and 15 mg with semaglutide 2.4 mg using an indirect treatment comparison.
Materials and Methods
Using SURMOUNT‐1 and STEP 1 trial data, mean percentage change in body weight from baseline and odds ratio (OR) of achieving 5% or greater weight loss were compared between tirzepatide 10 and 15 mg at week 72 and semaglutide 2.4 mg at week 68 using matching‐adjusted indirect comparison of the efficacy estimand. Sensitivity analyses were completed using different methods, including the Bucher method, also using different estimands and/or time points.
Results
Greater reductions in percentage change in body weight were observed with tirzepatide 10 and 15 mg versus semaglutide 2.4 mg (tirzepatide 10 mg mean difference: −4.67% [95% CI −5.91%, −3.43%]; tirzepatide 15 mg mean difference: −5.92% [95% CI −7.16%, −4.68%]; both P < .001). Similarly, more participants achieved 5% or greater weight loss with tirzepatide 10 mg (OR 2.61 [95% CI 1.48, 4.57]; P < .001) and 15 mg (OR 2.75 [95% CI 1.57, 4.81]; P < .001) compared with semaglutide 2.4 mg. All sensitivity analyses were consistent, except for an OR of achieving 5% or greater weight loss with tirzepatide 10 mg using the Bucher method to analyse the treatment regimen estimand (P = .074).
Conclusions
Currently there are no direct comparisons of tirzepatide and semaglutide for weight management. Using the matching‐adjusted indirect treatment comparison method to compare the efficacy of tirzepatide and semaglutide for chronic weight management, this analysis showed greater weight loss with tirzepatide 10 and 15 mg versus semaglutide 2.4 mg.</description><identifier>ISSN: 1462-8902</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/dom.15148</identifier><identifier>PMID: 37344384</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Body Weight ; Diabetes Mellitus, Type 2 ; Glucagon-Like Peptides - adverse effects ; Humans ; Hypoglycemic Agents ; incretin‐based therapies ; obesity ; Obesity - drug therapy ; semaglutide ; tirzepatide ; Weight Loss</subject><ispartof>Diabetes, obesity & metabolism, 2023-09, Vol.25 (9), p.2626-2633</ispartof><rights>2023 Eli Lilly & Company and The Authors. published by John Wiley & Sons Ltd.</rights><rights>2023 Eli Lilly & Company and The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3608-a0f8b5c41b8951155bcd1d6c2891f745eb0bedf897ff6030485513d06ec8b9bb3</citedby><cites>FETCH-LOGICAL-c3608-a0f8b5c41b8951155bcd1d6c2891f745eb0bedf897ff6030485513d06ec8b9bb3</cites><orcidid>0000-0002-2797-3545 ; 0000-0002-0179-6114 ; 0000-0003-3840-787X ; 0000-0001-5521-5445 ; 0000-0003-0111-1530</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdom.15148$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdom.15148$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37344384$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roux, Carel W.</creatorcontrib><creatorcontrib>Hankosky, Emily R.</creatorcontrib><creatorcontrib>Wang, Duzhe</creatorcontrib><creatorcontrib>Malik, Raleigh</creatorcontrib><creatorcontrib>Yu, Maria</creatorcontrib><creatorcontrib>Hickey, Ana</creatorcontrib><creatorcontrib>Kan, Hong</creatorcontrib><creatorcontrib>Bunck, Mathijs C.</creatorcontrib><creatorcontrib>Stefanski, Adam</creatorcontrib><creatorcontrib>Garcia‐Perez, Luis‐Emilio</creatorcontrib><creatorcontrib>Wharton, Sean</creatorcontrib><title>Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison</title><title>Diabetes, obesity & metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description>Aim
To compare the efficacy of tirzepatide 10 and 15 mg with semaglutide 2.4 mg using an indirect treatment comparison.
Materials and Methods
Using SURMOUNT‐1 and STEP 1 trial data, mean percentage change in body weight from baseline and odds ratio (OR) of achieving 5% or greater weight loss were compared between tirzepatide 10 and 15 mg at week 72 and semaglutide 2.4 mg at week 68 using matching‐adjusted indirect comparison of the efficacy estimand. Sensitivity analyses were completed using different methods, including the Bucher method, also using different estimands and/or time points.
Results
Greater reductions in percentage change in body weight were observed with tirzepatide 10 and 15 mg versus semaglutide 2.4 mg (tirzepatide 10 mg mean difference: −4.67% [95% CI −5.91%, −3.43%]; tirzepatide 15 mg mean difference: −5.92% [95% CI −7.16%, −4.68%]; both P < .001). Similarly, more participants achieved 5% or greater weight loss with tirzepatide 10 mg (OR 2.61 [95% CI 1.48, 4.57]; P < .001) and 15 mg (OR 2.75 [95% CI 1.57, 4.81]; P < .001) compared with semaglutide 2.4 mg. All sensitivity analyses were consistent, except for an OR of achieving 5% or greater weight loss with tirzepatide 10 mg using the Bucher method to analyse the treatment regimen estimand (P = .074).
Conclusions
Currently there are no direct comparisons of tirzepatide and semaglutide for weight management. Using the matching‐adjusted indirect treatment comparison method to compare the efficacy of tirzepatide and semaglutide for chronic weight management, this analysis showed greater weight loss with tirzepatide 10 and 15 mg versus semaglutide 2.4 mg.</description><subject>Body Weight</subject><subject>Diabetes Mellitus, Type 2</subject><subject>Glucagon-Like Peptides - adverse effects</subject><subject>Humans</subject><subject>Hypoglycemic Agents</subject><subject>incretin‐based therapies</subject><subject>obesity</subject><subject>Obesity - drug therapy</subject><subject>semaglutide</subject><subject>tirzepatide</subject><subject>Weight Loss</subject><issn>1462-8902</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp10D9P3DAYx3GrKioH7dA3UHlshxx2bCdOtxMFWukQC8yR_zw-XCXx1fYJHWJg5W3ySggXQF3w4mf46Dv8EPpKyZyO78iGfk4F5fIDmlFesYKysvq4u8tCNqTcRwcp_SWEcCbrT2if1YyPJ5-hu0sfb2GtsreAKcFqsJiKx_uHfoVN6NcqgsU3Pl_jBL1adZsdLOd8Ii5EnK8B5wgq9zBkHBwOGpLP2594MWA_WB_B5P_ElPUpDJ_RnlNdgi8v_yG6Oj25PP5dLC_O_hwvloVhFZGFIk5qYTjVshGUCqGNpbYypWyoq7kATTRYJ5vauYowwqUQlFlSgZG60Zodou9Tdx3Dvw2k3PY-Geg6NUDYpLaUpaxFKRgf6Y-JmhhSiuDadfS9ituWkvZ57HYcu92NPdpvL9mN7sG-ydd1R3A0gRvfwfb9Uvvr4nxKPgFXdor3</recordid><startdate>202309</startdate><enddate>202309</enddate><creator>Roux, Carel W.</creator><creator>Hankosky, Emily R.</creator><creator>Wang, Duzhe</creator><creator>Malik, Raleigh</creator><creator>Yu, Maria</creator><creator>Hickey, Ana</creator><creator>Kan, Hong</creator><creator>Bunck, Mathijs C.</creator><creator>Stefanski, Adam</creator><creator>Garcia‐Perez, Luis‐Emilio</creator><creator>Wharton, Sean</creator><general>Blackwell Publishing Ltd</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2797-3545</orcidid><orcidid>https://orcid.org/0000-0002-0179-6114</orcidid><orcidid>https://orcid.org/0000-0003-3840-787X</orcidid><orcidid>https://orcid.org/0000-0001-5521-5445</orcidid><orcidid>https://orcid.org/0000-0003-0111-1530</orcidid></search><sort><creationdate>202309</creationdate><title>Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison</title><author>Roux, Carel W. ; Hankosky, Emily R. ; Wang, Duzhe ; Malik, Raleigh ; Yu, Maria ; Hickey, Ana ; Kan, Hong ; Bunck, Mathijs C. ; Stefanski, Adam ; Garcia‐Perez, Luis‐Emilio ; Wharton, Sean</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3608-a0f8b5c41b8951155bcd1d6c2891f745eb0bedf897ff6030485513d06ec8b9bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Body Weight</topic><topic>Diabetes Mellitus, Type 2</topic><topic>Glucagon-Like Peptides - adverse effects</topic><topic>Humans</topic><topic>Hypoglycemic Agents</topic><topic>incretin‐based therapies</topic><topic>obesity</topic><topic>Obesity - drug therapy</topic><topic>semaglutide</topic><topic>tirzepatide</topic><topic>Weight Loss</topic><toplevel>online_resources</toplevel><creatorcontrib>Roux, Carel W.</creatorcontrib><creatorcontrib>Hankosky, Emily R.</creatorcontrib><creatorcontrib>Wang, Duzhe</creatorcontrib><creatorcontrib>Malik, Raleigh</creatorcontrib><creatorcontrib>Yu, Maria</creatorcontrib><creatorcontrib>Hickey, Ana</creatorcontrib><creatorcontrib>Kan, Hong</creatorcontrib><creatorcontrib>Bunck, Mathijs C.</creatorcontrib><creatorcontrib>Stefanski, Adam</creatorcontrib><creatorcontrib>Garcia‐Perez, Luis‐Emilio</creatorcontrib><creatorcontrib>Wharton, Sean</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes, obesity & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roux, Carel W.</au><au>Hankosky, Emily R.</au><au>Wang, Duzhe</au><au>Malik, Raleigh</au><au>Yu, Maria</au><au>Hickey, Ana</au><au>Kan, Hong</au><au>Bunck, Mathijs C.</au><au>Stefanski, Adam</au><au>Garcia‐Perez, Luis‐Emilio</au><au>Wharton, Sean</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison</atitle><jtitle>Diabetes, obesity & metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2023-09</date><risdate>2023</risdate><volume>25</volume><issue>9</issue><spage>2626</spage><epage>2633</epage><pages>2626-2633</pages><issn>1462-8902</issn><eissn>1463-1326</eissn><abstract>Aim
To compare the efficacy of tirzepatide 10 and 15 mg with semaglutide 2.4 mg using an indirect treatment comparison.
Materials and Methods
Using SURMOUNT‐1 and STEP 1 trial data, mean percentage change in body weight from baseline and odds ratio (OR) of achieving 5% or greater weight loss were compared between tirzepatide 10 and 15 mg at week 72 and semaglutide 2.4 mg at week 68 using matching‐adjusted indirect comparison of the efficacy estimand. Sensitivity analyses were completed using different methods, including the Bucher method, also using different estimands and/or time points.
Results
Greater reductions in percentage change in body weight were observed with tirzepatide 10 and 15 mg versus semaglutide 2.4 mg (tirzepatide 10 mg mean difference: −4.67% [95% CI −5.91%, −3.43%]; tirzepatide 15 mg mean difference: −5.92% [95% CI −7.16%, −4.68%]; both P < .001). Similarly, more participants achieved 5% or greater weight loss with tirzepatide 10 mg (OR 2.61 [95% CI 1.48, 4.57]; P < .001) and 15 mg (OR 2.75 [95% CI 1.57, 4.81]; P < .001) compared with semaglutide 2.4 mg. All sensitivity analyses were consistent, except for an OR of achieving 5% or greater weight loss with tirzepatide 10 mg using the Bucher method to analyse the treatment regimen estimand (P = .074).
Conclusions
Currently there are no direct comparisons of tirzepatide and semaglutide for weight management. Using the matching‐adjusted indirect treatment comparison method to compare the efficacy of tirzepatide and semaglutide for chronic weight management, this analysis showed greater weight loss with tirzepatide 10 and 15 mg versus semaglutide 2.4 mg.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>37344384</pmid><doi>10.1111/dom.15148</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-2797-3545</orcidid><orcidid>https://orcid.org/0000-0002-0179-6114</orcidid><orcidid>https://orcid.org/0000-0003-3840-787X</orcidid><orcidid>https://orcid.org/0000-0001-5521-5445</orcidid><orcidid>https://orcid.org/0000-0003-0111-1530</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-8902 |
| ispartof | Diabetes, obesity & metabolism, 2023-09, Vol.25 (9), p.2626-2633 |
| issn | 1462-8902 1463-1326 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2828752534 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Body Weight Diabetes Mellitus, Type 2 Glucagon-Like Peptides - adverse effects Humans Hypoglycemic Agents incretin‐based therapies obesity Obesity - drug therapy semaglutide tirzepatide Weight Loss |
| title | Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T04%3A41%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tirzepatide%2010%20and%2015%E2%80%89mg%20compared%20with%20semaglutide%202.4%E2%80%89mg%20for%20the%20treatment%20of%20obesity:%20An%20indirect%20treatment%20comparison&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=Roux,%20Carel%20W.&rft.date=2023-09&rft.volume=25&rft.issue=9&rft.spage=2626&rft.epage=2633&rft.pages=2626-2633&rft.issn=1462-8902&rft.eissn=1463-1326&rft_id=info:doi/10.1111/dom.15148&rft_dat=%3Cproquest_cross%3E2828752534%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2828752534&rft_id=info:pmid/37344384&rfr_iscdi=true |